Zacks Research Predicts Weaker Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research lowered their Q3 2025 earnings per share estimates for Avanos Medical in a research report issued on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.30 per share for the quarter, down from their prior estimate of $0.43. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.

Separately, StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.

Avanos Medical Trading Down 1.7 %

NYSE:AVNS opened at $14.16 on Monday. Avanos Medical has a 12 month low of $14.12 and a 12 month high of $25.36. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $651.40 million, a price-to-earnings ratio of 41.65 and a beta of 1.17. The firm has a fifty day simple moving average of $15.77 and a two-hundred day simple moving average of $18.51.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million.

Insider Activity

In other news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the transaction, the senior vice president now directly owns 82,047 shares in the company, valued at $1,251,216.75. This trade represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Avanos Medical

Large investors have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in Avanos Medical during the 3rd quarter worth approximately $42,000. KBC Group NV grew its holdings in Avanos Medical by 63.0% during the third quarter. KBC Group NV now owns 2,833 shares of the company’s stock worth $68,000 after buying an additional 1,095 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Avanos Medical in the 4th quarter valued at $64,000. State of Wyoming raised its position in Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after buying an additional 2,923 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Avanos Medical by 493.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock valued at $129,000 after acquiring an additional 6,714 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.